Background
==========

Head and neck squamous cell carcinoma (HNSC) is the sixth most common and frequently lethal cancer worldwide, with about 350 000 cancer-related deaths per year \[[@b1-medscimonit-25-4485]\]. The current staging system has limitation in identifying high-risk HNSC because large variability in clinical outcomes was found in same-stage patients \[[@b2-medscimonit-25-4485]--[@b6-medscimonit-25-4485]\]. To identify high-risk HNSC patients, new prognostic biomarkers are urgently needed for guiding the personalized treatment.

Chemokines are a particular group of cytokines that were originally described as being chemotactic to leukocytes \[[@b7-medscimonit-25-4485]\]. They can bind to 7-transmembrane domain G-protein-coupled receptors that are predominantly expressed by leukocytes \[[@b8-medscimonit-25-4485]\]. Chemokines are classified into 4 different subgroups (CXC, CC, CX3C, or C) depending on the position of the conserved cysteine residue \[[@b9-medscimonit-25-4485]\]. Chemokines are closely associated with inflammation, immunity, tumor development, and prognosis \[[@b10-medscimonit-25-4485]--[@b12-medscimonit-25-4485]\]. Chemokines play vital roles in all phases of oncogenesis, tumor growth, angiogenesis, malignant transformation, and metastatic dissemination in HNSC patients \[[@b9-medscimonit-25-4485]--[@b13-medscimonit-25-4485]\]. Many studies have shown that these single biomarkers cannot be widely used for the prediction of tumor prognosis because of their controversial conclusions and the heterogeneity between tumors \[[@b14-medscimonit-25-4485]--[@b17-medscimonit-25-4485]\]. Risk stratification may require combined multiple-molecular biomarkers. The gene expression profiles were produced simultaneously by high-throughput sequencing during the past 2 decades. Therefore, we can use a bioinformatic discovery approach to identify a multiple-RNA classifier that can improve the prediction of overall survival in HNSC patients.

Material and Methods
====================

Data collection
---------------

The clinical data for age, gender, primary sites, and clinical stage were downloaded from the TCGA database using the cBioPortal platform (2018.12.01). The inclusion criteria were: (i) histological diagnosis of HNSC; and (ii) adequate clinical characteristics (gender, age, primary sites, clinical stage, overall survival status, and time). Altogether, 504 HNSC patients were included and randomly divided into the training set (n=252) and validation set (n=252, detail shown in [Table 1](#t1-medscimonit-25-4485){ref-type="table"}). The numbers of stage I, II, III, and IV patients were 20, 97, 104, and 283, respectively. In addition, 10 HNSC patients had received neoadjuvant chemoradiotherapy; the other 494 patients had not. There were 334 HNSC patients \<65 years, and the other 170 patients were \>65 years. A total of 371 patients were male, and the other 133 patients were female. The RNA expression data of level 3 were downloaded from the cBioPortal platform and normalized. Chemokines were selected for which the expression data of \>80% of HNSC patients were more than 0.

Statistical analysis
--------------------

In the training set (n=252), we estimated the expression of the selected chemokines with overall survival (OS) by using the univariate Cox model. The candidate chemokines with a p-value of less than 0.05 were used to construct a predictive model by a multivariate Cox model. We calculated the prognostic risk score by the selected chemokines and their regression coefficients in the multivariate Cox model \[[@b18-medscimonit-25-4485]--[@b20-medscimonit-25-4485]\], as follow: Risk Score=expCCL2 \* βCCL2+expCCL7 \* βCCL7+expCCL22 \* βCCL22+expXCL2 \* βXCL2+expCXCL5 \* βCXCL5+expCXCL8 \* βCXCL8+expCCR4 \* βCCR4+expCCR6 \* βCCR6+expCCR7 \* βCCR7+expXCR1 \* βXCR1+expCX3CR1 \* βCX3CR1 (exp=expression level; β=the regression coefficient derived from the multivariate Cox model). To plot the Kaplan-Meier curves in these sets, we classified the patients into low or high risk by the same cutoff point, based on the Youden index in the training set \[[@b21-medscimonit-25-4485]\]. Survival differences between different risk groups were assessed and compared by the Kaplan-Meier estimate and log-rank test in the training, validation, and entire set. The time-dependent receiver operating characteristic (ROC) curve analysis for this 11-chemokine signature was performed for the prediction ability of OS within 48 months by using the "survival ROC" package. If the *p* values were less than 0.05, the log-rank test, Cox regression analysis, and ROC curve analysis were considered to be significant.

Gene functional analysis
------------------------

To better understand the underlying function of these selected chemokines, the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were analyzed using the Database for Annotation Visualization and Integrated Discovery (DAVID) \[[@b22-medscimonit-25-4485]\].

Results
=======

Identification and selection of potential chemokines in the training set
------------------------------------------------------------------------

The research flow for the development of this prognostic signature is shown in [Figure 1](#f1-medscimonit-25-4485){ref-type="fig"}. Gene expression data of 46 chemokines were extracted from TCGA sequencing data, and we further fitted these 46 chemokines in the univariate Cox model for the training set (n=252, shown in [Supplementary Table 1](#s1-medscimonit-25-4485){ref-type="supplementary-material"}). Therefore, we identified 11 chemokines whose expressions were significantly correlated with OS (p\<0.05, shown in [Table 1](#t1-medscimonit-25-4485){ref-type="table"}). Among the 11 chemokines, the coefficients in univariate Cox regression of CCL2, CCL7, CXCL5, and CXCL7 in univariate Cox model were positive, indicating that their higher levels of gene expression were associated with worse prognosis. In contrast, the coefficients of CCL22, XCL2, CCR4, CCR6, CCR7, XCR1, and CX3CR1 were negative, indicating that their higher levels of gene expression were associated with better prognosis.

Comparisons of survival between low-risk and high-risk groups
-------------------------------------------------------------

The entire study cohort of 504 patients was randomly grouped into training (n=252) and validation (n=252) sets. Based on these chemokines and their regression coefficients in the multivariate Cox model, we calculated the risk scores for each patient in the training (n=252), validation (n=252), and entire (n=504) sets ([Figure 2](#f2-medscimonit-25-4485){ref-type="fig"}). Using the cutoff value of risk scores (0.83074), HNSC patients were divided into a low-risk group and a high-risk group for training (low-risk/high-risk: 94/158) and validation (low-risk/high-risk: 58/194) sets. After integrating analysis of these 2 sets, there were 152 low-risk patients and 352 high-risk patients in the entire set (n=504). As shown in [Figure 2](#f2-medscimonit-25-4485){ref-type="fig"}, high-risk HNSC patients tended to have higher risk of death in the training, validation, and entire sets.

[Table 2](#t2-medscimonit-25-4485){ref-type="table"} lists the comprehensive clinical features of HNSC patients in the low-risk and high-risk groups. As shown in [Figure 3A](#f3-medscimonit-25-4485){ref-type="fig"} and [Table 3](#t3-medscimonit-25-4485){ref-type="table"}, further validation of this 11-chemokine signature using Kaplan-Meier and log-rank analysis significantly predicted OS in the training \[hazard ratio (HR)=3.497, 95% confidence interval (CI)=2.142--5.711, p\<0.001\], validation (HR=3.575, 95% CI=1.988--6.390, p\<0.001), and entire (HR=3.324, 95% CI=2.363--4.939, p\<0.001) sets. These results indicated that high-risk HNSC patients had significantly shorter OS than low-risk patients.

Multivariate Cox model
----------------------

We further assessed whether this risk score was independent of these clinical factors (age, sex, clinical stage, and primary sites) by a multivariate Cox model. As shown in [Table 4](#t4-medscimonit-25-4485){ref-type="table"}, this integrated 11-chemokine signature was identified as an independent prognostic factor in the training, validation, and entire sets (all p\<0.001) for HNSC patients. Hence, our findings suggest that this integrated 11-chemokine signature may become a reliable and independent biomarker for the prediction of overall survival in HNSC patients.

ROC curve analysis
------------------

As shown in [Figure 3B](#f3-medscimonit-25-4485){ref-type="fig"}, the AUC values for predicting overall survival within 48 months in the training, validation, and entire sets were 0.71, 0.69, and 0.69, respectively, highlighting the validity of this 11-chemokine signature.

Gene functional analysis
------------------------

Gene functional analysis indicated 29 GO terms and 4 KEGG pathways which these 11 chemokines were enriched in ([Figure 4A, 4B](#f4-medscimonit-25-4485){ref-type="fig"}). The main 9 participating GO terms contained chemokine-mediated (GO: 0070098), inflammatory response (GO: 0006954), cellular response to interleukin-1 (GO: 00071347), neutrophil chemotaxis (GO: 0030593), cellular response to tumor necrosis factor (GO: 0071356), lymphocyte chemotaxis (GO: 0048247), monocyte chemotaxis (GO: 0002548), chemokine activity (GO: 0008009), and CCR chemokine receptor (GO: 0048020). The key involved KEGG pathways were chemokine signaling pathway (Kegg: 04062), cytokine-cytokine receptor (Kegg: 04060), NOD-like receptor signaling pathway (Kegg: 04621), and Malaria (Kegg: 05144).

Discussion
==========

Although the current tumor staging system has been used to define the risk stratification of HNSC for many years, it is inadequate at identifying high-risk HNSC patients \[[@b4-medscimonit-25-4485],[@b6-medscimonit-25-4485],[@b23-medscimonit-25-4485],[@b24-medscimonit-25-4485]\]. Inconsistent clinical outcomes always existed among the same-stage patients with HNSC \[[@b5-medscimonit-25-4485],[@b25-medscimonit-25-4485]\]. Many studies demonstrated that chemokine family genes play a pivotal role in tumor inflammation, immunity, progression, and metastasis \[[@b26-medscimonit-25-4485]--[@b29-medscimonit-25-4485]\]. A multiple-gene prognostic biomarker of chemokine family genes is urgently needed and may contribute to the identification of potential HNSC patients with worse prognosis. To identify this multiple-gene prognostic biomarker, we profiled chemokine ligands and their receptors by mining the RNA sequencing data of TCGA. Based on the bioinformatic discovery and validation method, we constructed an 11-chemokine signature that can improve the prognostic prediction of overall survival in HNSC patients. The clinical utility of this signature can improve the predictive ability of the current staging system. In addition, the clinical application of this signature could classify patients with HNSC into low-risk and high-risk groups after radical surgery. High-risk patients with HNSC had worse prognosis than low-risk patients. This signature may be used as an additional biomarker for identifying potentially high-risk patients, which may contribute to personalized treatment for HNSC.

There are 7 protective genes (CCL22, XCL2, CCR4, CCR6, CCR7, XCR1, CX3CR1) and 4 risk genes (CCL2, CCL7, CXCL5, CXCL8) in this 11-chemokine signature. Previous research indicated that CCL2 and CCL7 are associated with tumor proliferation, invasion, migration, and tumor burden \[[@b30-medscimonit-25-4485],[@b31-medscimonit-25-4485]\]. In HNSC cells, decreased CXCL5 expression inhibits cell proliferation and reduces cell migration and invasion *in vitro* and inhibits tumor formation *in vivo* \[[@b32-medscimonit-25-4485]\]. CXCL8 is known to be a promoter of angiogenesis and a regulator of cell growth and motility in HNSC \[[@b33-medscimonit-25-4485]\]. The serum level of CXCL8 was used to predict a lower survival rate in patients, because the chemokine promotes metastasis by neutrophil infiltration and stimulates vascular endothelial cell proliferation, survival, and migration \[[@b34-medscimonit-25-4485]--[@b36-medscimonit-25-4485]\].

Several studies found that CCR7 expression was significantly associated with nodal metastasis \[[@b37-medscimonit-25-4485]--[@b40-medscimonit-25-4485]\]. Tsujikawa et al. concluded that CCR4 expression in primary HNSCC cells may be an attractive diagnostic biomarker to predict lymph node metastasis and subsequent prognosis of HNSC patients \[[@b41-medscimonit-25-4485]\]. However, levels of CCL22 in the peripheral blood have no correlation with tumor stage of HNSC \[[@b42-medscimonit-25-4485]\]. A previous study showed that high expression of CCR7 was associated with disease-free survival and CCR4 was correlated with tumor site, showing higher immune-reactive scores in tumors of the oral cavity \[[@b24-medscimonit-25-4485]\]. CCR6 and CCR7 mRNA levels were significantly decreased in lymph node (+) patients with laryngeal squamous cell carcinoma (LSCC) \[[@b43-medscimonit-25-4485]\]. The prognostic effect of these remaining chemokines (XCL2, XCR1, and CX3CR1) in HNSC should be further explored.

We should acknowledge some potential limitations for this 11-chemokine signature. Firstly, gene enrichment analysis found that this 11-chemokine signature was mainly involved in 9 GO terms and 4 KEGG pathways., but the GO terms and KEGG pathways involved by these 11 chemokines were not confirmed by cell, animal, or clinical studies. Further studies may should be performed to provide potential therapeutic targets for HNSC. Secondly, only 46 chemokine family genes were selected for in this study. The connection between overall survival and mRNA levels of the remaining 14 chemokines should be studied by tumor specimens of HNSC furtherly. Thirdly, this 11-chemokine signature was constructed by a bioinformatic discovery and validation approach. This prognostic signature was not further verified by protein level data of Western blot or immunohistochemistry or RNA level data of quantitative reverse transcription polymerase chain reaction from clinical tumor specimens. Moreover, research in other databases is needed to verify the potential significance of this signature among different cohorts of HNSC patients.

Conclusions
===========

We performed a comprehensive analysis of chemokines mRNA expression profiles and clinical data of HNSC patients in the TCGA database. Then, we identified an 11-chemokine signature that may improve the prediction of overall survival in HNSC patients. This is the first study to demonstrate the link between an 11-chemokine signature and overall survival in HNSC patients. Our results may support useful risk stratification of overall survival in HNSC patients, which would contribute to gene target treatment for HNSC. However, this 11-chemokine signature should be further tested by tumor specimens of HNSC before clinical application.

Supplementary Table
===================

###### 

Univariate Cox regression analysis of chemokine family genes associated with overall survival in the training set (n=252, TCGA).

  Gene Symbol   Type       Sub-family   HR (95% CI)            Coefficient   p Value   Gene Symbol   Type       Sub-family   HR (95% CI)            Coefficient   p Value
  ------------- ---------- ------------ ---------------------- ------------- --------- ------------- ---------- ------------ ---------------------- ------------- ---------
  CCL2          Ligand     CC           1.173 (1.019--1.351)   0.16          0.026     CXCL9         Ligand     CXC          0.966 (0.894--1.042)   −0.035        0.371
  CCL3          Ligand     CC           1.13 (0.978--1.305)    0.122         0.097     CXCL10        Ligand     CXC          1.006 (0.935--1.082)   0.006         0.878
  CCL7          Ligand     CC           1.154 (1.027--1.296)   0.143         0.016     CXCL11        Ligand     CXC          1.028 (0.957--1.103)   0.027         0.452
  CCL11         Ligand     CC           1.024 (0.916--1.146)   0.024         0.671     CXCL12        Ligand     CXC          1.054 (0.923--1.204)   0.053         0.434
  CCL13         Ligand     CC           1.07 (0.952--1.203)    0.068         0.256     CXCL14        Ligand     CXC          0.956 (0.881--1.036)   −0.045        0.274
  CCL14         Ligand     CC           0.992 (0.897--1.097)   −0.008        0.876     CXCL16        Ligand     CXC          1.079 (0.823--1.415)   0.076         0.583
  CCL17         Ligand     CC           0.912 (0.796--1.044)   −0.092        0.183     CXCL17        Ligand     CXC          0.933 (0.867--1.004)   −0.069        0.064
  CCL18         Ligand     CC           0.997 (0.896--1.109)   −0.003        0.954     CXCR1         Receptor   CXC          0.997 (0.904--1.098)   −0.003        0.945
  CCL19         Ligand     CC           0.945 (0.875--1.021)   −0.056        0.153     CXCR2         Receptor   CXC          0.917 (0.824--1.019)   −0.087        0.108
  CCL20         Ligand     CC           1.03 (0.948--1.12)     0.03          0.48      CXCR3         Receptor   CXC          0.909 (0.82--1.008)    −0.096        0.069
  CCL21         Ligand     CC           0.928 (0.858--1.004)   −0.075        0.063     CXCR4         Receptor   CXC          0.871 (0.745--1.017)   −0.138        0.081
  CCL22         Ligand     CC           0.857 (0.746--0.985)   −0.154        0.03      CXCR6         Receptor   CXC          0.886 (0.78--1.007)    −0.121        0.064
  CCL23         Ligand     CC           1.079 (0.912--1.275)   0.076         0.375     XCL1          Ligand     XC           0.959 (0.85--1.083)    −0.041        0.503
  CCL24         Ligand     CC           1 (0.876--1.143)       0             0.997     XCL2          Ligand     XC           0.856 (0.74--0.99)     −0.155        0.037
  CCL27         Ligand     CC           1.014 (0.891--1.155)   0.014         0.83      XCR1          Receptor   XC           0.831 (0.73--0.946)    −0.185        0.005
  CCL28         Ligand     CC           0.917 (0.801--1.049)   −0.087        0.207     CX3CL1        Ligand     CX3C         1.008 (0.904--1.124)   0.008         0.885
  CCR1          Receptor   CC           1.07 (0.928--1.233)    0.067         0.352     CX3CR1        Receptor   CX3C         0.859 (0.752--0.981)   −0.152        0.025
  CCR3          Receptor   CC           1.014 (0.816--1.261)   0.014         0.899     CXCL2         Ligand     CXC          1.062 (0.948--1.188)   0.06          0.299
  CCR4          Receptor   CC           0.888 (0.8--0.985)     −0.119        0.025     CXCL3         Ligand     CXC          1.074 (0.965--1.196)   0.072         0.191
  CCR6          Receptor   CC           0.772 (0.652--0.915)   −0.258        0.003     CXCL5         Ligand     CXC          1.113 (1.008--1.23)    0.107         0.01
  CCR7          Receptor   CC           0.846 (0.752--0.951)   −0.167        0.005     CXCL6         Ligand     CXC          1.053 (0.966--1.148)   0.052         0.241
  CCR8          Receptor   CC           0.961 (0.849--1.088)   −0.039        0.533     CXCL8         Ligand     CXC          1.14 (1.031--1.261)    0.131         0.011
  CCR10         Receptor   CC           0.909 (0.785--1.052)   −0.096        0.201                                                                                

CI -- confidence index; HR -- hazard ratio.
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![Identification and performance evaluation of these 11 chemokines signature in training, validation, and entire sets. (**A**) Kaplan-Meier survival curve analysis for overall survival of HNSC patients using the 11-chemokines signature in these 3 datasets. (**B**) ROC curve analysis of the 11-chemokines signature in these 3 datasets.](medscimonit-25-4485-g003){#f3-medscimonit-25-4485}

![Gene function and pathway analysis. (**A**) GO enrichment analysis. (**B**) Significant pathway analysis.](medscimonit-25-4485-g004){#f4-medscimonit-25-4485}

###### 

The characteristics of 11 chemokines associated with overall survival in the training set of 252 HNSC patients (n=252, TCGA).

  Gene symbol   Type       HR (95% CI)   Coefficients   p Value   Putative function
  ------------- ---------- ------------- -------------- --------- -------------------
  CCL2          Ligand     1.173         0.16           0.026     Risky
  CCL7          Ligand     1.154         0.143          0.016     Risky
  CCL22         Ligand     0.857         −0.154         0.03      Protective
  XCL2          Ligand     0.856         −0.155         0.037     Protective
  CXCL5         Ligand     1.113         0.107          0.01      Risky
  CXCL8         Ligand     1.14          0.131          0.011     Risky
  CCR4          Receptor   0.888         −0.119         0.025     Protective
  CCR6          Receptor   0.772         −0.258         0.003     Protective
  CCR7          Receptor   0.846         −0.167         0.005     Protective
  XCR1          Receptor   0.831         −0.185         0.005     Protective
  CX3CR1        Receptor   0.859         −0.152         0.025     Protective

CI -- confidence index; HR -- hazard ratio.

###### 

Clinical characteristics of HNSC patients according to this 11-chemokine classifier in the training (n=252, TCGA), validation (n=252, TCGA), and entire (n=504, TCGA) sets.

  Characteristics      Training set (n=252)   Validation set (n=252)   Entire set (n=504)                                   
  -------------------- ---------------------- ------------------------ -------------------- ----- ----- ------- ----- ----- -------
  Age                                                                                                                       
   \<65y               96                     65                       0.180                132   41    0.703   228   106   0.279
   ≥65y                62                     29                       62                   17    124   46                  
  Gender                                                                                                                    
   Male                114                    71                       0.557                144   42    0.518   258   113   0.807
   Female              44                     23                       50                   16    94    39                  
  Stage                                                                                                                     
   I--II               32                     23                       0.433                43    19    0.100   75    42    0.050
   III--IV             126                    71                       151                  39    277   110                 
  Primary sites                                                                                                             
   Oral cavity         109                    73                       0.137                146   45    0.716   255   118   0.223
  Pharynx and larynx   49                     21                       48                   13    97    34                  

###### 

Log-rank test of overall survival according to this 11-ckemokine classifier in the training (n=252), validation (n=252), and entire (n=504) sets.

  Datasets                 Risk group (n)      Disease-free survival                                          
  ------------------------ ------------------- ----------------------- ------- ------- ---------------------- ---------
  Training set (n=252)     High-risk (n=158)   76.5%                   40.4%   33.1%   3.497 (2.142--5.711)   \<0.001
  Low-risk (n=94)          97.9%               82.3%                   65.7%                                  
  Validation set (n=252)   High-risk (n=194)   76.4%                   50.7%   38.2%   3.575 (1.988--6.390)   \<0.001
  Low-risk (n=58)          96.5%               80.6%                   76.9%                                  
  Entire set (n=504)       High-risk (n=352)   76.4%                   46.1%   36.0%   3.416 (2.363--4.939)   \<0.001
  Low-risk (n=152)         97.3%               81.6%                   69.3%                                  

CI -- confidence index; HR -- hazard ratio.

###### 

Multivariate Cox regression analysis of this eleven-chemokine classifier, gender, age, stage, and primary sites for overall survival in the training (n=252), validation (n=252), and entire (n=504) sets.

  Datasets                                           Variable                                                 Disease-free Survival   
  -------------------------------------------------- -------------------------------------------------------- ----------------------- ---------
  Training set (n=246)                               The 11-chemokine classifier (high- *vs.* low-risk)       3.557 (2.165--5.845)    \<0.001
  Age (≥65 years *vs.* \<65 years)                   1.562 (1.056--2.312)                                     0.026                   
  Gender (Female *vs.* Male)                         1.66 (1.081--2.548)                                      0.021                   
  Tumor stage (II--IV *vs.* I--II)                   0.999 (0.614--1.626)                                     0.998                   
  Primary sites (oral cavity *vs.* pharynx/larynx)   0.964 (0.617--1.505)                                     0.87                    
  Validation set (n=246)                             The eleven-chemokine classifier (high- *vs.* low-risk)   3.442 (1.919--6.172)    \<0.001
  Age (≥65 years *vs.* \<65 years)                   1.009 (0.672--1.515)                                     0.97                    
  Gender (Female *vs.* Male)                         1.065 (0.688--1.647)                                     0.78                    
  Tumor stage (II--IV *vs.* I--II)                   1.226 (0.780--1.927)                                     0.38                    
  Primary sites (oral cavity *vs.* pharynx/larynx)   0.741 (0.462--1.188)                                     0.21                    
  Entire set (n=504)                                 The eleven-chemokine classifier (high- *vs.* low-risk)   3.360 (2.320--4.867)    \<0.001
  Age (≥65 years *vs.* \<65 years)                   1.250 (0.944--1.654)                                     0.117                   
  Gender (Female *vs.* Male)                         1.301 (0.962--1.759)                                     0.088                   
  Tumor stage (II--IV *vs.* I--II)                   1.097 (0.789--1.525)                                     0.579                   
  primary sites (oral cavity *vs.* pharynx/larynx)   0.860 (0.622--1.188)                                     0.361                   

HR -- hazard ratio; NR -- not reported; CI -- confidence index.
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